Inflammatory Bowel Disease Treatment Market Report
RA00784
Inflammatory Bowel Disease Treatment Market by Type (Crohn's Disease and Ulcerative Colitis), Drug Class (Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, and Others), Route of Administration (Oral and Injectable), Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032
Inflammatory Bowel Disease Treatment Overview
Inflammatory Bowel Disease (IBD) treatment typically involves a combination of medications, lifestyle changes, and, in severe cases, surgery. The main goals of treatment are to reduce inflammation, control symptoms, and improve the patient's quality of life. Common medications used in IBD treatment include anti-inflammatory drugs, immunosuppressants, and biological therapies. Lifestyle changes may include dietary modifications, stress management, and regular exercise.
Global Inflammatory Bowel Disease Treatment Market Analysis
The global inflammatory bowel disease treatment market size was $20.35 billion in 2022 and is predicted to grow with a CAGR of 3.91%, by generating a revenue of $29.35 billion by 2032.
COVID-19 Impact on Global Inflammatory Bowel Disease Treatment Market
During the peak of the pandemic, many healthcare facilities were overwhelmed with COVID-19 cases, leading to the postponement or cancellation of non-urgent medical procedures, including routine check-ups and IBD treatments. This disruption affected patients' access to necessary medications and treatments, potentially leading to disease exacerbation for some. To minimize the risk of infection, healthcare providers increasingly adopted telemedicine and virtual consultations. While this allowed continued access to healthcare, including IBD management, it might not have been as effective as in-person visits for certain cases that required physical examinations and close monitoring. The pandemic disrupted global supply chains, leading to shortages of some medications used in IBD treatment. Although efforts were made to ensure the continuous supply of essential drugs, certain regions might have experienced difficulties in obtaining medications, affecting patient care.
The use of telemedicine and virtual healthcare is persisting as it offers convenience and improved access to specialists, especially for patients in remote areas. Healthcare systems and providers are more prepared to handle future disruptions, ensuring better continuity of care for patients with chronic conditions like IBD. The experience with COVID-19 has highlighted the importance of investing in research and development for novel treatments, which led to advancements in IBD therapies.
Increasing Awareness About IBD and Its Symptoms Among People to Drive the Market Growth
Increasing awareness about IBD and its symptoms among healthcare professionals and the general population has led to earlier diagnosis. Early detection allows for timely treatment and better disease management, driving the demand for IBD treatments. Improved reimbursement policies by governments and private insurance companies for IBD treatments make these therapies more accessible and affordable for patients. This encourages patients to seek appropriate medical care and supports market growth. Growing healthcare expenditure in many countries allows for increased investment in research and development, leading to the discovery of new and more effective treatment options for IBD. Improvements in healthcare infrastructure, particularly in developing regions, enhance access to healthcare services and treatments for IBD, boosting the inflammatory bowel disease treatment market growth.
Significant Side Effects Associated with IBD Treatments to Restrain Market Growth
IBD treatments can be expensive, especially biologic therapies and immunomodulators, which can limit access for some patients and strain healthcare budgets. Some IBD treatments can cause significant side effects, leading to treatment discontinuation or reduced patient compliance. Currently, there is no cure for IBD, and existing treatments primarily focus on managing symptoms and reducing inflammation. The absence of curative options remains a significant restraint for patients. Accurate diagnosis and monitoring of IBD can be complex, leading to delays in initiating appropriate treatment and potentially impacting disease management.
Ongoing Research and Development in Biological Drugs to Drive Excellent Opportunities
Ongoing research and development in biological drugs targeting specific molecules in the immune system present opportunities for more effective and targeted IBD treatments. The development of personalized treatment approaches based on genetic profiling and biomarkers can enhance treatment efficacy and reduce adverse effects for individual patients. The growing adoption of telemedicine and digital health platforms allows better remote monitoring, patient engagement, and adherence to treatment plans, improving overall disease management. While biologics have been a significant advancement, they are often administered through injections or infusions. Developing effective oral therapies for IBD could improve patient convenience and adherence to treatment regimens. The increasing availability and acceptance of biosimilars offer cost-effective alternatives to biological treatments, potentially expanding access to IBD therapies. The development of orally administered drugs may provide convenient and non-invasive treatment options for patients who prefer or cannot tolerate injections or infusions.
Global Inflammatory Bowel Disease Treatment Market Share, by Type, 2022
The Crohn’s disease sub-segment accounted for the highest market share in 2022. For the treatment of Crohn's disease, more biological therapies and immunomodulators are available. For the management of Crohn's disease, these treatments have gone through significant research and gained authorization. Ulcerative Colitis is more uncommon than Crohn's disease amongst individuals who have IBD, hence research and medication development efforts are focused more on it. Historically, Crohn's disease has received more focus in IBD research, leading to a greater understanding of its pathophysiology and potential therapy options. Because of its higher frequency and complexity, clinical trials for potential IBD treatments are primarily focused on Crohn's disease.
Global Inflammatory Bowel Disease Treatment Market Share, by Drug Class, 2022
The TNF inhibitors sub-segment accounted for the highest market share in 2022. The significant market share can be due to the rise in the rate of TNF inhibitor prescriptions for the treatment of IBD and the growing consumer awareness of TNF inhibitors. The popular TNF inhibitors used to treat inflammatory diseases include Humira, Remicade, Simponi, Cimzia, and other biosimilars.
Global Inflammatory Bowel Disease Treatment Market Share, by Route of Administration, 2022
The injectable sub-segment accounted for the highest market share in 2022. Some medications used in IBD treatment have better bioavailability when administered through injection. The digestive system can break down and metabolize certain drugs before they reach the bloodstream when taken orally, leading to reduced effectiveness. Injections allow for more targeted delivery of medications, ensuring that the drug reaches the specific affected areas in the gastrointestinal tract more effectively. This is particularly important in IBD, where inflammation can occur at various locations along the digestive tract. Injectable medications can have a faster onset of action compared to oral forms since they do not have to be processed through the digestive system before being absorbed.
Global Inflammatory Bowel Disease Treatment Market Share, by Distribution, 2022
The hospital pharmacy sub-segment accounted for the highest market share in 2022. Severe cases of IBD may require hospitalization for intensive treatment and management. Hospital pharmacies play a crucial role in providing timely and appropriate medications to patients during their stay. Many IBD treatments, especially biologics, are administered through intravenous infusion. Hospital pharmacies are equipped to prepare and administer these medications safely and accurately. In acute flares or complications of IBD, patients may require immediate medical attention and treatment. Hospital pharmacies ensure that the necessary medications are available promptly in emergency situations. Besides, hospital pharmacies have experience in managing the procurement, storage, and handling of these drugs, which may require specific temperature conditions or handling procedures.
Global Inflammatory Bowel Disease Treatment Market Share, by Region, 2022
The North America inflammatory bowel disease treatment market generated the largest revenue in 2022. The dominance of the region can be attributed to the presence of many prominent market players and the numerous strategic initiatives implemented by them. In addition, the region's improved reimbursement practices, high treatment rates, and rising prescription of new therapies are facilitating regional expansion. The region's expansion is anticipated to be fuelled by ongoing attempts to discover innovative therapies and supportive government initiatives.
Competitive Scenario in the Global Inflammatory Bowel Disease Treatment Market
There are several major players functioning in the highly competitive global inflammatory bowel disease treatment market. In order to increase their market presence and boost their product portfolios pharmaceutical companies invest in research and development to create new and improved medications for IBD treatment. This includes the development of novel biologic therapies, small molecule inhibitors, and targeted drugs.
Some of the leading inflammatory bowel disease treatment market players are AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Lilly, UCB S.A., CELLTRION INC., Merck & Co., Inc., and Johnson & Johnson Services, Inc.
| Aspect | Particulars |
| Historical Market Estimations | 2021 |
| Base Year for Market Estimation | 2022 |
| Forecast Timeline for Market Projection | 2023-2032 |
| Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
| Segmentation by Type |
|
| Segmentation by Drug Class |
|
| Segmentation by Route of Administration |
|
| Segmentation by Distribution |
|
| Key Companies Profiled |
|
Q1. What is the size of the inflammatory bowel disease treatment market?
A. The size of the inflammatory bowel disease treatment market was over $20.35 billion in 2022 and is expected to reach $29.35 billion by 2032.
Q2. Which are the major companies in the inflammatory bowel disease treatment market?
A. AbbVie Inc, Takeda Pharmaceutical Company Limited, and Pfizer Inc. are some of the key players in the global inflammatory bowel disease treatment market.
Q3. Which region, among others, possesses greater investment opportunities in the future?
A. North America region possesses great investment opportunities for investors in the future.
Q4. What are the strategies opted by the leading players in this market?
A. Product development and R&D investment are the key strategies opted by the operating companies in this market.
Q5. Which companies are investing more on R&D practices?
A. AbbVie Inc, Takeda Pharmaceutical Company Limited, and Pfizer Inc. are investing more on R&D activities.
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Inflammatory Bowel Disease (IBD) Treatment Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Inflammatory Bowel Disease (IBD) Treatment Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Inflammatory Bowel Disease (IBD) Treatment Market, By Gender
5.1. Overview
5.2 Crohn’s Disease
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Ulcerative Colitis
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Research Dive Exclusive Insights
5.4.1 Market attractiveness
5.4.2 Competition heatmap
-
6. Inflammatory Bowel Disease (IBD) Treatment Market, By Treatment
6.1. Overview
6.2 Injectables
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Oral
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Research Dive Exclusive Insights
6.4.1 Market attractiveness
6.4.2 Competition heatmap
-
7. Inflammatory Bowel Disease (IBD) Treatment Market, By Location
7.1. Overview
7.2 Hospital Pharmacy
7.2.1 Definition, key trends, growth factors, and opportunities
7.2.2 Market size analysis, by region, 2020-2027
7.2.3 Market share analysis, by country, 2020-2027
7.3 Retail Pharmacy
7.3.1 Definition, key trends, growth factors, and opportunities
7.3.2 Market size analysis, by region, 2020-2027
7.3.3 Market share analysis, by country, 2020-2027
7.4 Online Pharmacy
7.4.1 Definition, key trends, growth factors, and opportunities
7.4.2 Market size analysis, by region, 2020-2027
7.4.3 Market share analysis, by country, 2020-2027
7.5 Research Dive Exclusive Insights
7.5.1 Market attractiveness
7.5.2 Competition heatmap
8. Inflammatory Bowel Disease (IBD) Treatment Market, By Region
8.1 North America
8.1.1 U.S
8.1.1.1 Market size analysis, By Gender, 2020-2027
8.1.1.2 Market size analysis, By Treatment, 2020-2027
8.1.1.3 Market size analysis, By Location, 2020-2027
8.1.2 Canada
8.1.2.1 Market size analysis, By Gender, 2020-2027
8.1.2.2 Market size analysis, By Treatment, 2020-2027
8.1.2.3 Market size analysis, By Location, 2020-2027
8.1.3 Mexico
8.1.3.1 Market size analysis, By Gender, 2020-2027
8.1.3.2 Market size analysis, By Treatment, 2020-2027
8.1.3.3 Market size analysis, By Location, 2020-2027
8.1.4 Research Dive Exclusive Insights
8.1.4.1 Market attractiveness
8.1.4.2 Competition heatmap
8.2 Europe
8.2.1 Germany
8.2.1.1 Market size analysis, By Gender, 2020-2027
8.2.1.2 Market size analysis, By Treatment, 2020-2027
8.2.1.3 Market size analysis, By Location, 2020-2027
8.2.2 UK
8.2.2.1 Market size analysis, By Gender, 2020-2027
8.2.2.2 Market size analysis, By Treatment, 2020-2027
8.2.2.3 Market size analysis, By Location, 2020-2027
8.2.3 France
8.2.3.1 Market size analysis, By Gender, 2020-2027
8.2.3.2 Market size analysis, By Treatment, 2020-2027
8.2.3.3 Market size analysis, By Location, 2020-2027
8.2.4 Spain
8.2.4.1 Market size analysis, By Gender, 2020-2027
8.2.4.2 Market size analysis, By Treatment, 2020-2027
8.2.4.3 Market size analysis, By Location, 2020-2027
8.2.5 Italy
8.2.5.1 Market size analysis, By Gender, 2020-2027
8.2.5.2 Market size analysis, By Treatment, 2020-2027
8.2.5.3 Market size analysis, By Location, 2020-2027
8.2.6 Rest of Europe
8.2.6.1 Market size analysis, By Gender, 2020-2027
8.2.6.2 Market size analysis, By Treatment, 2020-2027
8.2.6.3 Market size analysis, By Location, 2020-2027
8.2.7 Research Dive Exclusive Insights
8.2.7.1 Market attractiveness
8.2.7.2 Competition heatmap
8.3 Asia-Pacific
8.3.1 China
8.3.1.1 Market size analysis, By Gender, 2020-2027
8.3.1.2 Market size analysis, By Treatment, 2020-2027
8.3.1.3 Market size analysis, By Location, 2020-2027
8.3.2 Japan
8.3.2.1 Market size analysis, By Gender, 2020-2027
8.3.2.2 Market size analysis, By Treatment, 2020-2027
8.3.2.3 Market size analysis, By Location, 2020-2027
8.3.3 India
8.3.3.1 Market size analysis, By Gender, 2020-2027
8.3.3.2 Market size analysis, By Treatment, 2020-2027
8.3.3.3 Market size analysis, By Location, 2020-2027
8.3.4 Australia
8.3.4.1 Market size analysis, By Gender, 2020-2027
8.3.4.2 Market size analysis, By Treatment, 2020-2027
8.3.4.3 Market size analysis, By Location, 2020-2027
8.3.5 South Korea
8.3.5.1 Market size analysis, By Gender, 2020-2027
8.3.5.2 Market size analysis, By Treatment, 2020-2027
8.3.5.3 Market size analysis, By Location, 2020-2027
8.3.6 Rest of Asia-Pacific
8.3.6.1 Market size analysis, By Gender, 2020-2027
8.3.6.2 Market size analysis, By Treatment, 2020-2027
8.3.6.3 Market size analysis, By Location, 2020-2027
8.3.7 Research Dive Exclusive Insights
8.3.7.1 Market attractiveness
8.3.7.2 Competition heatmap
8.4 LAMEA
8.4.1 Brazil
8.4.1.1 Market size analysis, By Gender, 2020-2027
8.4.1.2 Market size analysis, By Treatment, 2020-2027
8.4.1.3 Market size analysis, By Location, 2020-2027
8.4.2 Saudi Arabia
8.4.2.1 Market size analysis, By Gender, 2020-2027
8.4.2.2 Market size analysis, By Treatment, 2020-2027
8.4.2.3 Market size analysis, By Location, 2020-2027
8.4.3 UAE
8.4.3.1 Market size analysis, By Gender, 2020-2027
8.4.3.2 Market size analysis, By Treatment, 2020-2027
8.4.3.3 Market size analysis, By Location, 2020-2027
8.4.4 South Africa
8.4.4.1 Market size analysis, By Gender, 2020-2027
8.4.4.2 Market size analysis, By Treatment, 2020-2027
8.4.4.3 Market size analysis, By Location, 2020-2027
8.4.5 Rest of LAMEA
8.4.5.1 Market size analysis, By Gender, 2020-2027
8.4.5.2 Market size analysis, By Treatment, 2020-2027
8.4.5.3 Market size analysis, By Location, 2020-2027
8.4.6 Research Dive Exclusive Insights
8.4.6.1 Market attractiveness
8.4.6.2 Competition heatmap
9. Competitive Landscape
9.1 Top winning strategies, 2020-2027
9.1.1 By strategy
9.1.2 By year
9.2 Strategic overview
9.3 Market share analysis, 2020-2027
10. Company Profiles
10.1 Johnson & Johnson Services Inc.
10.1.1 Overview
10.1.2 Business segments
10.1.3 Product portfolio
10.1.4 Financial performance
10.1.5 Recent developments
10.1.6 SWOT analysis
10.2 Pfizer Inc.
10.2.1 Overview
10.2.2 Business segments
10.2.3 Product portfolio
10.2.4 Financial performance
10.2.5 Recent developments
10.2.6 SWOT analysis
10.3 Takeda Pharmaceutical Company Limited
10.3.1 Overview
10.3.2 Business segments
10.3.3 Product portfolio
10.3.4 Financial performance
10.3.5 Recent developments
10.3.6 SWOT analysis
10.4 AbbVie Inc.
10.4.1 Overview
10.4.2 Business segments
10.4.3 Product portfolio
10.4.4 Financial performance
10.4.5 Recent developments
10.4.6 SWOT analysis
10.5 Celltrion Healthcare Co., Ltd.
10.5.1 Overview
10.5.2 Business segments
10.5.3 Product portfolio
10.5.4 Financial performance
10.5.5 Recent developments
10.5.6 SWOT analysis
10.6 CELGENE CORPORATION
10.6.1 Overview
10.6.2 Business segments
10.6.3 Product portfolio
10.6.4 Financial performance
10.6.5 Recent developments
10.6.6 SWOT analysis
10.7 COSMO PHARMACEUTICALS
10.7.1 Overview
10.7.2 Business segments
10.7.3 Product portfolio
10.7.4 Financial performance
10.7.5 Recent developments
10.7.6 SWOT analysis
10.8 Innovate Biopharmaceuticals
10.8.1 Overview
10.8.2 Business segments
10.8.3 Product portfolio
10.8.4 Financial performance
10.8.5 Recent developments
10.8.6 SWOT analysis
10.9 UCB S.A.
10.9.1 Overview
10.9.2 Business segments
10.9.3 Product portfolio
10.9.4 Financial performance
10.9.5 Recent developments
10.9.6 SWOT analysis
10.10 and Gilead Sciences
10.10.1 Overview
10.10.2 Business segments
10.10.3 Product portfolio
10.10.4 Financial performance
10.10.5 Recent developments
10.10.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
